Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 89 C41 | DOI: 10.1530/endoabs.89.C41

1Division of Medical Oncology, University of Kentucky; 2Department of Pathology, University of Kentucky; 3Department of Biostatistics, University of Kentucky; 4Markey Cancer Center, University of Kentucky.

Background: Somatostatin receptor (SSTR) expression has been characterized in well-differentiated neuroendocrine tumors (NET). However, the understanding of receptor expression in various non-neuroendocrine solid tumors is limited. This study was performed to evaluate SSTR-2 in various cancers to provide a rational basis for SSTR-2 targeted anti-cancer therapies.

Methods: Formalin-fixed paraffin, paraffin-embedded tissue was obtained from pathology archives after institutional review board approval. Tumor blocks were prospectively stained with an anti-SSTR-2 antibody via immunohistochemistry (IHC). The following tumor types were studied: small cell carcinoma (Code 0; n=14), medullary thyroid cancer (Code 1, n=10), melanoma (Code 2, n=10), merkel cell carcinoma (Code 3, n=10), head and neck p16 positive squamous cell carcinoma (Code 4, n=10), well-differentiated NET (Code 5, n=10), paraganglioma and pheochromocytoma (Code 6, n=20), poorly differentiated neuroendocrine carcinoma (Code 7, n=9), and p16 negative squamous cell cancer (Code 8, n=4). IHC was scored as follows: SSTR2 Intensity (0=none, 1=weak, 2=moderate, 3=strong), SSTR2 Localization (1= membranous; 2=cytoplasmic; 3=mixed), SSTR2 % Positivity (5% increments)

Results: 64% of SCLC samples stained positive for SSTR-2, and 35.7 % of SCLC samples stained strongly positive for SSTR-2. 60% of Head and Neck carcinoma samples stained positive for SSTR-2, and 40% of these were of moderate intensity. As expected, 100% well-differentiated NET samples stained positive for SSTR-2. Only 33% of poorly differentiated neuroendocrine carcinoma samples were stained positive for SSTR-2, out of which only 11 % stained strongly positive for SSTR-2.

Conclusions: As expected, well-differentiated NET expressed very high SSTR-2 positivity with high intensity. However, a subset of small cell carcinoma and head and neck p16 positive squamous cell carcinoma were observed to express SSTR-2. Targeting SSTR-2 in small cell carcinoma and head and neck cancer with the help of radiolabeled somatostatin analog could be a promising therapeutic approach. Based on our SSTR-2 IHC data, a prospective study of SSTR-2 assessment with the help of gallium 68 dotatate PET imaging in small cell lung cancer patients is currently underway at Markey Cancer Center.

Abstract ID 21481

Article tools

My recent searches

No recent searches.